McKesson Corporation vs Oklo Inc — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while Oklo Inc trades at $35.08 (market cap $6.43B). The key difference: McKesson Corporation is far larger — about 16.9× Oklo Inc's market cap, and McKesson Corporation pays a 0.4% dividend while Oklo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Oklo Inc for 31 Days on average.
| MCK | OKLO | |
|---|---|---|
Market Cap | $108.46B | $6.43B |
Volume | 712,607 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $995.69 | $174.14 |
52-Week Low | $725.17 | $34.57 |
Typical Hold Time | 74 Days | 31 Days |
Enterprise Value | $115.00B | $3.97B |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
OKLO trades at $36.82, down 4.49% with bearish technical signals. The company shows no revenue in 2025 and negative net income of -$105.66M, with profitability metrics deeply negative. Recent earnings have missed expectations in two of the last three quarters. However, analyst sentiment remains strong with 71% buy ratings and a $78.63 consensus price target, reflecting optimism about the nuclear energy opportunity.
The outlook balances high growth potential in the nuclear sector against significant execution risks. While the $10 trillion nuclear opportunity and partnerships with hyperscalers provide upside, OKLO faces challenges including negative cash flow from operations, substantial dilution from recent stock sales, and intense competition in the small modular reactor market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →